©2024 Stanford Medicine
Prostate Active Surveillance Study
Recruiting
I'm InterestedTrial ID: NCT00756665
Purpose
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen
active surveillance as a management plan for their prostate cancer. Active surveillance is
defined as close monitoring of prostate cancer with the offer of treatment if there are
changes in test results. This study seeks to discover markers that will identify cancers that
are more aggressive from those tumors that grow slowly.
Official Title
Canary Prostate Active Surveillance Study
Stanford Investigator(s)
James D. Brooks
Keith and Jan Hurlbut Professor
Benjamin I. Chung
Associate Professor of Urology
Harcharan Gill
Kathryn Simmons Stamey Professor, Emeritus
Eligibility
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy.
- Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
- No previous treatment for prostate cancer (including hormonal therapy, radiation
therapy, surgery, or chemotherapy).
- ECOG Performance Status 0 or 1.
- Patient has elected Active Surveillance as preferred management plan for prostate
cancer.
- Patient consent has been obtained according to local Institutional Review Board for
acquisition of research specimens.
- Patient is accessible and compliant for follow-up.
- Prostate cancer diagnosis cannot be more than 3 years prior to baseline visit date.
- No more than two prostate biopsies including the initial biopsy in which cancer was
diagnosed.
- If cancer diagnosis is more than one year before enrollment, there must be two
prostate biopsies including the initial biopsy in which cancer was diagnosed and a
subsequent biopsy. The subsequent biopsy may occur on the same day as the baseline
visit.
- Biopsies must have at least 10 cores.
Exclusion Criteria:
- Unwillingness or inability to undergo serial prostate biopsy.
- History of other malignancies, except: adequately treated non-melanoma skin cancer or
adequately treated superficial bladder cancer (Ta) or other solid tumors curatively
treated with no evidence of disease for > 5 years.
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michelle Ferrari
650-725-5543